US Stock MarketDetailed Quotes
CRBU Caribou Biosciences
- 2.200
- +0.180+8.91%
Close Nov 27 16:00 ET
- 2.150
- -0.050-2.27%
Post 20:01 ET
199.22MMarket Cap-1325P/E (TTM)
2.200High2.000Low2.11MVolume2.040Open2.020Pre Close4.48MTurnover2.58%Turnover RatioLossP/E (Static)90.55MShares8.33052wk High0.71P/B179.47MFloat Cap1.50052wk Low--Dividend TTM81.58MShs Float32.645Historical High--Div YieldTTM9.90%Amplitude1.500Historical Low2.127Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Caribou Biosciences Stock Forum
$Gossamer Bio (GOSS.US)$
$Archer Aviation (ACHR.US)$
Gonna add a position for each again.
Caribou Biosciences Announces the FDA Has Granted Fast Track Designations to CB-010 in Refractory Sle and to CB-012 in Relapsed or Refractory Aml
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Caribou Biosciences presented promising clinical data from its CB-010 ANTLER Phase 1 trial at the 2024 ASCO Annual Meeting. CB-010, an allogeneic CAR-T cell therapy with partial HLA matching, showed potential to rival currently approved autologous CAR-T therapies in safety an...
Benzinga· 4 mins ago
- FDA has cleared Caribou's IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 --
-- Driven by encouraging initial safety and efficacy in the ongoing ANTLER trial for r/r B-NHL, CB-010 clinical development has expanded to include autoimmune diseases --
-- Advancing ANT...
The regulator found a proposed comparator arm of platinum-based immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation to be "acceptable," the compan...
No comment yet